Author Interviews, Breast Cancer, JAMA, Surgical Research / 02.08.2017
Repeated Breast-Conserving Surgeries Come With Significant Complications and Costs
MedicalResearch.com Interview with:
[caption id="attachment_36272" align="alignleft" width="80"]
Dr. Jacobs[/caption]
Dr. Lisa K. Jacobs MD
Johns Hopkins School of Medicine
Baltimore, Maryland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Breast preservation is the preferred treatment for many women diagnosed with breast cancer. The most common question that a patient will ask after the surgery is, “Did you get it all?” In the ideal case, this is accomplished in a single outpatient surgery with very good cosmetic results. In our study, Beyond the Margins-Economic Costs and Complications Associated with Repeated Breast-Conserving Surgeries we evaluated the detrimental effects of an unsuccessful initial surgery due to positive surgical margins. Using private insurance claims data, we found that 16% of patients planning breast preservation required a second breast-conserving surgery and an additional 7% converted to mastectomy. Of those patients that required additional surgery there was a 56% ($16,072) increase in cost and a 48% increase in complications. Those complications include infection, hematoma, seroma, and fat necrosis. This study demonstrates that repeated surgery has not only cosmetic consequences, but also has financial implications and increased risk.
Dr. Jacobs[/caption]
Dr. Lisa K. Jacobs MD
Johns Hopkins School of Medicine
Baltimore, Maryland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Breast preservation is the preferred treatment for many women diagnosed with breast cancer. The most common question that a patient will ask after the surgery is, “Did you get it all?” In the ideal case, this is accomplished in a single outpatient surgery with very good cosmetic results. In our study, Beyond the Margins-Economic Costs and Complications Associated with Repeated Breast-Conserving Surgeries we evaluated the detrimental effects of an unsuccessful initial surgery due to positive surgical margins. Using private insurance claims data, we found that 16% of patients planning breast preservation required a second breast-conserving surgery and an additional 7% converted to mastectomy. Of those patients that required additional surgery there was a 56% ($16,072) increase in cost and a 48% increase in complications. Those complications include infection, hematoma, seroma, and fat necrosis. This study demonstrates that repeated surgery has not only cosmetic consequences, but also has financial implications and increased risk.
Dr. Wactawski-Wende[/caption]
Jean Wactawski-Wende, PhD
Dean, SUNY Distinguished Professor
Professor, Department of Epidemiology and Environmental Health
School of Public Health and Health Professions
University of Buffalo
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There has been a growing interest in the role of periodontal disease in system chronic diseases, including cancer. We explored the association of periodontal disease history and incident cancer in the women's health initiative study of postmenopausal women. We found that women reporting periodontal disease history were at increased risk of developing cancer overall. In addition they were found to have significant increased risk of specific cancers including cancers of the lung, breast, esophagus, gallbladder and melanoma. The risk persisted after control for many other factors. In addition, the risk was seen in women regardless of their smoking history. Both ever smokers and never smokers were found to have increased risk of cancer associated with periodontal disease history.
Dr. Adrian Harel[/caption]
Dr. Adrian Harel, PhD
Chief Executive Officer
Medicortex Finland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Every 15 seconds, someone in the United States suffers a new head injury. Of the 2.5M people treated in hospital emergency rooms each year, 80,000 become permanently disabled because of TBI. Currently, there are no reliable diagnostic tests to assess the presence or severity of an injury on-site, nor are there any pharmaceutical therapies that could stop the secondary injury from spreading. Accurate diagnostics would benefit especially mild cases of TBI (concussions), which, if occurring repeatedly, may cause neurodegenerative conditions such as Chronic Traumatic Encephalopathy (which is typical for athletes in NFL and Ice-hockey).
We have performed extensive preclinical research comparing fluid biopsies from normal and injured lab animals. The results showed some unique biomarkers released as a biodegradation products after head injury. The data served as the basis and confirmation for our patent applications to protect the biomarker concept.
Medicortex has completed a clinical proof-of-concept trial in collaboration with Turku University Hospital (Tyks). Samples from 12 TBI patients and 12 healthy volunteers were collected and analyzed for the presence and for the level of the biomarker in state-of-the-art laboratories. The study demonstrated the diagnostic potential of the new biomarker in humans and it confirmed the prior preclinical findings. This was a significant milestone for Medicortex.


















